RANKL subcellular trafficking and regulatory mechanisms in osteocytes

Journal of Bone and Mineral Research

Volumn 28, Issue 9, 2013, Pages 1936-1949

  Honma, Masashi ^a   Ikebuchi, Yuki ^a   Kariya, Yoshiaki ^a   Hayashi, Madoka ^a   Hayashi, Naoki ^a   Aoki, Shigeki ^a   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

OPG; OSTEOCLASTOGENESIS; OSTEOCYTE; RANKL; SUBCELLULAR TRAFFIC

Indexed keywords

COLLAGEN GEL; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOTINYLATION; CALVARIA; CELL MIGRATION; CELL STIMULATION; CELL STRUCTURE; CELL SURFACE; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; FIBROBLAST; IN VITRO STUDY; LYSOSOME STORAGE DISEASE; MARKER GENE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; PRECURSOR; PROTEIN EXPRESSION; REGULATORY MECHANISM;

OPG; OSTEOCLASTOGENESIS; OSTEOCYTE; RANKL; SUBCELLULAR TRAFFIC;

ANIMALS; BONE MARROW CELLS; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELL MEMBRANE; COLLAGEN; DENDRITES; LYSOSOMES; MACROPHAGES; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OSTEOCLASTS; OSTEOCYTES; OSTEOGENESIS; OSTEOPROTEGERIN; POROSITY; PROTEIN TRANSPORT; RANK LIGAND; SUBCELLULAR FRACTIONS;

EID: 84882688846     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1941     Document Type: Article

References (34)

1. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95(7):3597-602.
2. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13(18):2412-24.
3. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-23.
4. Abu-Amer Y, Abbas S, Hirayama T. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. J Cell Biochem. 2004;93(5):980-9.
5. Dai JC, He P, Chen X, Greenfield EM. TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone. 2006;38(4):509-20.
6. Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res. 2000;15(7):1321-9.
7. Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003;14(3-4):251-63.
8. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231-4.
9. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235-41.
10. Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, Tamura M, Takahashi N, Suda T. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology. 1996;137(8):2187-90.
11. Nakahama K. Cellular communications in bone homeostasis and repair. Cell Mol Life Sci. 2010;67(23):4001-9.
12. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/ RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone. 1999;25(5):517-23.
13. Aoki S, Honma M, Kariya Y, Nakamichi Y, Ninomiya T, Takahashi N, Udagawa N, Suzuki H. Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis. J Bone Miner Res. 2010;25 (9):1907-21.
14. Kariya Y, Honma M, Aoki S, Chiba A, Suzuki H. Vps33a mediates RANKL storage in secretory lysosomes in osteoblastic cells. J Bone Miner Res. 2009;24(10):1741-52.
15. Kariya Y, Honma M, Hanamura A, Aoki S, Ninomiya T, Nakamichi Y, Udagawa N, Suzuki H. Rab27a and Rab27b are involved in stimulation-dependent RANKL release from secretory lysosomes in osteoblastic cells. J Bone Miner Res. 2011;26(4):689-703.
16. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26 (2):229-38.
17. Dallas SL, Bonewald LF. Dynamics of the transition from osteoblast to osteocyte. Ann NY Acad Sci. 2010;1192:437-43.
18. Gu G, Nars M, Hentunen TA, Metsikko K, Vaananen HK. Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res. 2006;323(2):263-71.
19. Li X, Udagawa N, Takami M, Sato N, Kobayashi Y, Takahashi N. p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology. 2003;144(11):4999- 5005.
20. Sato N, Takahashi N, Suda K, Nakamura M, Yamaki M, Ninomiya T, Kobayashi Y, Takada H, Shibata K, Yamamoto M, Takeda K, Akira S, Noguchi T, Udagawa N. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J Exp Med. 2004;200(5):601-11.
21. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerindeficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260-8.
22. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S-I, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Biochem Biophys Res Commun. 1998;247(3): 610-5.
23. Boukhechba F, Balaguer T, Michiels JF, Ackermann K, Quincey D, Bouler JM, Pyerin W, Carle GF, Rochet N. Human primary osteocyte differentiation in a 3D culture system. J Bone Miner Res. 2009;24 (11):1927-35.
24. Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF. Establishment of an osteocyte-like cell line. MLO-Y4. J Bone Miner Res. 1997;12 (12):2014-23.
25. Matsuo K. Osteocytes communicate with osteoclast lineage cells via RANKL. IBMS BoneKEy. 2012;9:39.
26. Zhao S, Kato Y, Zhang YK, Harris S, Ahuja SS, Bonewald LF. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res. 2002;17(11):2068-79.
27. Hill PA. Bone remodelling. Br J Orthod. 1998;25(2):101-7.
28. Koutsilieris M, Sourla A, Pelletier G, Doillon CJ. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer. J Bone Miner Res. 1994;9 (11):1823-32.
29. Murshid SA, Kamioka H, Ishihara Y, Ando R, Sugawara Y, Takano- Yamamoto T. Actin and microtubule cytoskeletons of the processes of 3D-cultured MC3T3-E1 cells and osteocytes. J Bone Miner Metab. 2007;25(3):151-8.
30. Bennett JH, Carter DH, Alavi AL, Beresford JN, Walsh S. Patterns of integrin expression in a human mandibular explant model of osteoblast differentiation. Arch Oral Biol. 2001;46(3):229-38.
31. Hughes DE, Salter DM, Dedhar S, Simpson R. Integrin expression in human bone. J Bone Miner Res. 1993;5:527-33.
32. McNamara LM, Majeska RJ, Weinbaum S, Friedrich V, Schaffler MB. Attachment of osteocyte cell processes to the bone matrix. Anat Rec. 2009;292(3):355-63.
33. Hikita A, Yana I, Wakeyama H, Nakamura M, Kadono Y, Oshima Y, Nakamura K, Seiki M, Tanaka S. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem. 2006;281(48):36846-55.
34. Schlondorff J, Lum L, Blobel CP. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem. 2001;276(18):14665-74.